Bormioli Pharma
Bormioli Pharma, a leading name in the pharmaceutical packaging industry, is headquartered in Italy and operates extensively across Europe and beyond. Founded in 1927, the company has established itself as a pioneer in the design and production of glass and plastic containers, primarily serving the pharmaceutical, healthcare, and cosmetic sectors. Bormioli Pharma is renowned for its innovative solutions, including high-quality vials, bottles, and closures that ensure product safety and integrity. The company’s commitment to sustainability and advanced manufacturing processes sets it apart in a competitive market. With a strong focus on research and development, Bormioli Pharma has achieved significant milestones, solidifying its position as a trusted partner for global pharmaceutical companies.
DitchCarbon Score
How does Bormioli Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Paper Products industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bormioli Pharma's score of 20 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bormioli Pharma's reported carbon emissions
In 2023, Bormioli Pharma reported total carbon emissions of approximately 134,185,000 kg CO2e for Scope 1 and 2 combined, and about 95,334,000 kg CO2e for Scope 3 emissions. This reflects a continued focus on managing their carbon footprint across various operational scopes. Over the years, Bormioli Pharma has shown a trend of emissions management, with Scope 1 emissions increasing from about 34,236,000 kg CO2e in 2018 to approximately 38,865,000 kg CO2e in 2020, while Scope 2 emissions have fluctuated, peaking at about 130,519,000 kg CO2e in 2019. Notably, their Scope 3 emissions have remained significant, with figures around 466,090,000 kg CO2e in 2018, decreasing to approximately 84,536,000 kg CO2e in 2022, and further to about 95,334,000 kg CO2e in 2023. Despite these figures, Bormioli Pharma has not publicly committed to specific reduction targets or initiatives as part of their climate strategy. The absence of documented reduction targets suggests a need for further clarity on their long-term climate commitments. The company continues to navigate the complexities of emissions management within the pharmaceutical industry, focusing on transparency and accountability in their environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 34,236,000 | 00,000,000 | 00,000,000 | - | - | - |
| Scope 2 | 126,371,000 | 000,000,000 | 000,000,000 | - | - | - |
| Scope 3 | 466,090,000 | 000,000,000 | 000,000,000 | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Bormioli Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
